JP2008545753A5 - - Google Patents

Download PDF

Info

Publication number
JP2008545753A5
JP2008545753A5 JP2008514858A JP2008514858A JP2008545753A5 JP 2008545753 A5 JP2008545753 A5 JP 2008545753A5 JP 2008514858 A JP2008514858 A JP 2008514858A JP 2008514858 A JP2008514858 A JP 2008514858A JP 2008545753 A5 JP2008545753 A5 JP 2008545753A5
Authority
JP
Japan
Prior art keywords
composition
growth factor
composition according
monoclonal antibody
nrg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008514858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008545753A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/021293 external-priority patent/WO2006130773A2/en
Publication of JP2008545753A publication Critical patent/JP2008545753A/ja
Publication of JP2008545753A5 publication Critical patent/JP2008545753A5/ja
Pending legal-status Critical Current

Links

JP2008514858A 2005-06-02 2006-06-01 抗体で脳腫瘍を処置する方法 Pending JP2008545753A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68711805P 2005-06-02 2005-06-02
US75109205P 2005-12-15 2005-12-15
PCT/US2006/021293 WO2006130773A2 (en) 2005-06-02 2006-06-01 Methods of treating brain tumors with antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013002317A Division JP2013136580A (ja) 2005-06-02 2013-01-10 抗体で脳腫瘍を処置する方法

Publications (2)

Publication Number Publication Date
JP2008545753A JP2008545753A (ja) 2008-12-18
JP2008545753A5 true JP2008545753A5 (cg-RX-API-DMAC7.html) 2009-05-07

Family

ID=37482322

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008514858A Pending JP2008545753A (ja) 2005-06-02 2006-06-01 抗体で脳腫瘍を処置する方法
JP2013002317A Pending JP2013136580A (ja) 2005-06-02 2013-01-10 抗体で脳腫瘍を処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013002317A Pending JP2013136580A (ja) 2005-06-02 2013-01-10 抗体で脳腫瘍を処置する方法

Country Status (14)

Country Link
US (2) US20070036797A1 (cg-RX-API-DMAC7.html)
EP (1) EP1885400A4 (cg-RX-API-DMAC7.html)
JP (2) JP2008545753A (cg-RX-API-DMAC7.html)
KR (1) KR20080026562A (cg-RX-API-DMAC7.html)
AU (1) AU2006252419B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0611009A2 (cg-RX-API-DMAC7.html)
CA (1) CA2607699A1 (cg-RX-API-DMAC7.html)
CR (1) CR9512A (cg-RX-API-DMAC7.html)
IL (1) IL187318A0 (cg-RX-API-DMAC7.html)
MA (1) MA29570B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007015056A (cg-RX-API-DMAC7.html)
NO (1) NO20080012L (cg-RX-API-DMAC7.html)
RU (1) RU2007146986A (cg-RX-API-DMAC7.html)
WO (1) WO2006130773A2 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ566395A (en) 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US7649083B2 (en) 2006-06-02 2010-01-19 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding antibody
AU2007254853B2 (en) * 2006-06-02 2011-11-17 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
DK2066694T3 (en) * 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
EA201000337A1 (ru) * 2007-08-24 2010-10-29 Новартис Аг Модулятор nrg1 для лечения респираторных расстройств
TW200948380A (en) * 2008-04-11 2009-12-01 Galaxy Biotech Llc Combination of HGF inhibitor and PTEN agonist to treat cancer
WO2009126840A1 (en) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
KR101590495B1 (ko) * 2008-05-29 2016-02-01 갤럭시 바이오테크, 엘엘씨 염기성 섬유모세포 성장 인자에 대한 모노클로날 항체
WO2010119991A2 (en) 2009-04-17 2010-10-21 Takeda Pharmaceutical Company Limited Novel method of treating cancer
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
US9556249B2 (en) * 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
RU2439160C1 (ru) * 2010-06-25 2012-01-10 Государственное общеобразовательное учреждение высшего профессионального образования "Российский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО РГМУ Росздрава) Способ получения моноклональных антител к аблюминальному мембранному антигену церебральных эндотелиоцитов
US20130315895A1 (en) * 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
JP2000515735A (ja) * 1996-07-03 2000-11-28 ジェネンテック インコーポレーテッド 肝細胞成長因子レセプターアゴニスト
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
US7977345B2 (en) * 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
WO2007056523A2 (en) * 2005-11-08 2007-05-18 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CL2009000843A1 (es) * 2008-04-11 2009-07-24 Galaxy Biotech Llc Metodo para tratar cancer en un paciente que comprende la administracion de un primer agente que es inhibidor de factor de crecimiento de hepatocito (hgf) en combinacion con un segundo agente que es inhibidor de una ruta de senalizacion celular diferente de la ruta hgf/cmet.
WO2009126840A1 (en) * 2008-04-11 2009-10-15 Galaxy Biotech, Llc Combination of hgf inhibitor and hedgehog inhibitor to treat cancer

Similar Documents

Publication Publication Date Title
JP2008545753A5 (cg-RX-API-DMAC7.html)
RU2007146986A (ru) Способы лечения опухолей головного мозга с использованием антител
Pasquier et al. Angiocrine endothelium: from physiology to cancer
Slichenmyer et al. Anticancer therapy targeting the erbB family of receptor tyrosine kinases
Kazanis et al. Alterations in IGF-I, BDNF and NT-3 levels following experimental brain trauma and the effect of IGF-I administration
Barrientos et al. Growth factors and cytokines in wound healing
Im et al. Induction of striatal neurogenesis enhances functional recovery in an adult animal model of neonatal hypoxic-ischemic brain injury
KR102317700B1 (ko) 피부 섬유성 장애를 치료하는 조성물 및 방법
Emanueli et al. Paracrine control of vascularization and neurogenesis by neurotrophins
JP2013522313A5 (cg-RX-API-DMAC7.html)
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
Kaneko et al. A 3D nanofibrous hydrogel and collagen sponge scaffold promotes locomotor functional recovery, spinal repair, and neuronal regeneration after complete transection of the spinal cord in adult rats
US20080241157A1 (en) Nerve cell growth modulators (amphibodies)
JP2013512877A5 (cg-RX-API-DMAC7.html)
Hom et al. Growth factor therapy to improve soft tissue healing
JP2019521156A5 (cg-RX-API-DMAC7.html)
Daneshimehr et al. Angiogenesis and its targeting in glioblastoma with focus on clinical approaches
Krishnan et al. Combination of epidermal growth factor receptor targeted therapy with radiation therapy for malignant gliomas
RU2015143217A (ru) Самособирающиеся синтетические белки
Han Growth factor therapy
Pan et al. Receptor-mediated transport of LIF across blood–spinal cord barrier is upregulated after spinal cord injury
Saban et al. VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCG
Yu et al. Time-dependent effect of combination therapy with erythropoietin and granulocyte colony-stimulating factor in a mouse model of hypoxic-ischemic brain injury
Ohkawara et al. Hepatocyte growth factor fusion protein having collagen-binding activity (CBD-HGF) accelerates re-endothelialization and intimal hyperplasia in balloon-injured rat carotid artery
Asai et al. Successful treatment of diabetic gangrene with topical application of a mixture of peripheral blood mononuclear cells and basic fibroblast growth factor